SpeeDx and Nepean Hospital Awarded Federal Funding for Viral Respiratory Biomarker Test
3.9.2020 06:34:00 EEST | Business Wire | Press release
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, in partnership with researchers from Nepean Blue Mountains Local Health District’s (NBMLHD) Nepean Hospital Intensive Care Unit were awarded funding through the MTPConnect Biomedical Translation Bridge (BTB) program. Funds will support the commercialisation of a respiratory virus host response test – a rapid-response assay to enhance current COVID-19 management activities and future viral pandemic preparedness.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200902005970/en/
Utilising newly patented InSignia(TM) technology that enhances the measurement of gene expression, the test will be a rapid, high-throughput tool to support risk-based stratification of patients presenting with respiratory viral illness, including COVID-19. (photo: Sara Eshleman/Wikimedia Commons)
SpeeDx are adapting the NBMLHD laboratory developed test that targets a key genetic marker that is uniquely expressed in response to respiratory virus infection, with levels of the marker correlated with disease progression.1,2 Utilising newly patented In SigniaTM technology that enhances the measurement of gene expression, the commercial test will be a rapid, high-throughput tool to support risk-based stratification of patients presenting with respiratory viral illness, including COVID-19.
“The MTPConnect BTB funding will be instrumental in advancing our commercialisation process and supporting the tight timelines we are setting in order to bring this important product to market” said Colin Denver, SpeeDx CEO.
Delivered by MTPConnect, the Australian Government's BTB program is a $22.3 million MRFF initiative that provides up to $1 million in matched funding to nurture the translation of new therapies, technologies and medical devices through to proof of concept to turn innovative medical ideas into reality.
About SpeeDx
Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com
About Nepean and Blue Mountains Local Health District
Nepean Blue Mountains Local Health District is well placed to draw on over 100 years of continuously caring for the community, conducting research and delivering innovation. The Nepean Hospital Intensive Care Unit is part of NBMLHD’s 5,700-strong staff. Being on the frontline of health means NBMLHD has a focus on practical solutions that deliver maximum impact to the health and wellbeing of patients and their families.
References
- Tang BM et al. Eur Respir J. 2017 Jun 15;49(6):1602098.
- https://www.smh.com.au/national/covid-19-blood-test-to-predict-which-patients-will-need-the-most-care-20200406-p54hja.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200902005970/en/
Contact information
SpeeDx
Australia, New Zealand and Europe
Madeline O’Donoghue - SpeeDx
+61 406 582 808
United States
Rick Roose - RCI Healthcare Public Relations
+1 415 202 4445
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression17.2.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint in the ongoing Phase 3 COMP006 trial, the second of two Phase 3 trials, which is evaluating two fixed doses of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). The primary endpoint was the difference in change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) scores between the 25 mg and 1 mg groups at Week 6. Two fixed doses – administered 3 weeks apart – of COMP360 25 mg versus 1 mg demonstrated a highly statistically significant reduction in symptom severity with a p-value of <0.001 and a clinically meaningful difference of -3.8 points in change at the primary endpoint. Across COMP005 and COMP006 to date, COMP360 is demonstrating a generally well-tolerated and safe profile, with treatment-emergent adverse events (
BeOne Medicines to Present at Upcoming Investor Conferences17.2.2026 13:00:00 EET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in fireside chats at four upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 am ET; Leerink Global Healthcare Conference on Monday, March 9, 2026 at 11:20 am ET; Citizens Life Sciences Conference on Tuesday, March 10, 2026 at 9:35 am ET; and Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 3:00 pm ET Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel the
CTC Global Launches GridVista System and Strategic Partnership with Google Cloud and Tapestry to Transform Grid Intelligence17.2.2026 13:00:00 EET | Press release
CTC Global, the world’s leading developer and manufacturer of high-capacity advanced conductors, today announced the launch of the GridVista System. The GridVista System provides utilities with real-time, high-resolution data to optimize grid capacity, prevent outages, reduce wildfire risk, and lower operational costs. With the launch of the GridVista System, CTC is also announcing a deepening of its strategic partnership with Google Cloud and Tapestry—Alphabet’s moonshot for the electric grid. GridVista System’s unprecedented line awareness, paired with Google Cloud and Tapestry’s AI-powered tools, will transform line data into actionable intelligence for the grid. The GridVista System redefines transmission line intelligence by utilizing optical fibers embedded directly within CTC Global’s ACCC Conductor. Unlike legacy technology that relies on external sensors to estimate line conditions, GridVista provides direct visibility into strain, temperature, and vibration across the entire
Kingspan Insulation Chooses Expereo to Unify Connectivity and Accelerate Growth Across 90 Global Sites17.2.2026 11:00:00 EET | Press release
Expereo, the world-leading managed Network as a Service (NaaS) provider that connects people, places and things anywhere, announces that Kingspan Insulation, the global manufacturer of premium and high-performance insulation products and systems, has selected Expereo to deliver a fully managed connectivity solution across its worldwide operations. Expereo’s solution enables Kingspan Insulation to consolidate its complex network of disparate ISPs into a single, centralised, fully managed solution - enhancing visibility, compliance, and agility to enable rapid growth and scalability of Kingspan Insulation’s operations. Kingspan Insulation manages a complex WAN environment with 90 sites globally across multiple vendors - which creates significant challenges in terms of efficient connectivity, compliance and security. With the business moving away from MPLS and embracing SaaS and cloud services, the need for resilient, standardized, and agile connectivity has become critical. Kingspan Insu
Ohana Development Launches USD 4.1 Billion ‘Manchester City Yas Residences by Ohana’ in Abu Dhabi17.2.2026 10:51:00 EET | Press release
Ohana Development, a leading UAE real estate developer, has officially launched ‘Manchester City Yas Residences by Ohana,’ a USD 4.1 billion gated waterfront community on Yas Canal in Abu Dhabi and Manchester City F.C.’s first branded residential project globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260216102386/en/ Manchester City Yas Residences by Ohana (Photo: AETOSWire) The project was launched at Etihad Park in Abu Dhabi, in the presence of Husein Salem, CEO, and Mustafa El Sammak, COO, of Ohana Development as well as Ferran Soriano, CEO of City Football Group. During the event, the Abu Dhabi Real Estate Centre announced the digitisation of Expressions of Interest and booking processes for off-plan purchases through its Madhmoun platform, introducing a new regulated framework in Abu Dhabi. Registrations will operate under ADREC’s direct supervision with mandatory escrow management, strengthening investor prot
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom